The Papillary Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Papillary Thyroid Cancer. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Papillary Thyroid Cancer by 25 companies/universities/institutes. The top development phase for Papillary Thyroid Cancer is phase ii with 20 drugs in that stage. The Papillary Thyroid Cancer pipeline has 29 drugs in development by companies and two by universities/ institutes. Some of the companies in the Papillary Thyroid Cancer pipeline products market are: Jiangsu Hengrui Medicine, Novartis and Boston Children’s Hospital.
The key targets in the Papillary Thyroid Cancer pipeline products market include Vascular Endothelial Growth Factor Receptor 2, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, and Serine/Threonine Protein Kinase B Raf.
The key mechanisms of action in the Papillary Thyroid Cancer pipeline product include Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor with five drugs in Phase III. The Papillary Thyroid Cancer pipeline products include seven routes of administration with the top ROA being Oral and eight key molecule types in the Papillary Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Papillary Thyroid Cancer overview
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes in the neck or other parts of the body. The main symptom of PTC is a painless lump or nodule on the thyroid gland, which can be detected by physical examination or ultrasound. The diagnosis of PTC is confirmed by a fine needle aspiration (FNA) biopsy, which samples cells from the nodule for microscopic analysis. The treatment of PTC depends on the size, stage, and aggressiveness of the tumor, but it usually involves surgery to remove the thyroid gland (thyroidectomy) and radioactive iodine therapy to destroy any remaining cancer cells. PTC has a very good prognosis, with a survival rate of over 90% after 10 years.
For a complete picture of Papillary Thyroid Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
